Bladder Cancer Awareness Month | Early Signs Matter | Prioritize Your Urological Health

Understanding Bladder Cancer

• Bladder cancer is one of the most common cancers of the urinary tract, yet public awareness remains limited. 
• Early symptoms are often mistaken for minor infections. Watch out for with early diagnosis and timely treatment, bladder cancer is highly manageable.

 Introduction 

• Bladder cancer is the most common malignancy involving the urinary system. Urothelial (transitional cell) carcinoma is the predominant histologic type, where it accounts for 90 percent of all bladder cancers. In other areas of the world, non-urothelial carcinomas are more frequent. Much less commonly, urothelial cancers can arise in the renal pelvis, ureter, or urethra.
• The spectrum of bladder cancer includes non-muscle invasive (superficial), muscle-invasive, and metastatic disease, each with its own clinical behavior, biology, prognosis, and treatment.  

Growing Burden – Epidemiology 

• Bladder cancer is the tenth most common cancer in the world. 
• Globally, there were approximately 500,000 new cases and over 210,000 deaths in 2020.
• Bladder cancer is relatively rare in the Indian population, ranking 17th in incidence and 19th in mortality. The incidence rate is higher in males than females, with a male-to-female ratio of 4:1 in urban areas.
• According to the GLOBOCAN 2022 report, India reports over 22,000 new cases annually, with men being 4 times more affected than women. Unfortunately, many cases go undetected in the early stages due to a lack of awareness and routine checkups.
• Delhi has the highest incidence rates among males (7.4) and females (1.7). 
• The incidence rate in males is 2.4% and in females is 0.7%. 
• There were 18,921 new cases and 10,231 deaths in India. 
• The overall incidence rate is 2.25 per 100,000 annually

Risk Factors

• Age >55, and male gender
• Chemical carcinogenesis – Cigarette smoke, cannabis, opium smoke, Tobacco use (the leading cause)
• Occupational carcinogen exposure – metal workers, painters, rubber industry workers, leather workers, textile and electrical workers, miners, cement workers, transport operators, excavating-machine operators, and jobs that involve manufacture of carpets, paints, plastics, and industrial chemicals
• Contaminated water (arsenic exposure) –  high concentrations of arsenic in drinking water and the subsequent development of bladder cancer
• Chronic bladder infections – Repeated chronic irritation can lead to metaplastic changes, then dysplasia, and finally carcinoma.
• Iatrogenic Risk Factors – Analgesic, Radiation therapy
• Others – Air pollution, hair dyes, use od artificial sweeteners 

Sign And Symptoms 

• Painless gross hematuria – Approximately 80-90% of patients; classic presentation.
• Irritative bladder symptoms (eg, dysuria, urgency, frequency of urination) – 20-30% of patients.
• Pelvic or bony pain, lower-extremity edema, or flank pain – In patients with advanced disease.
• Palpable mass on physical examination – Rare in superficial bladder cancer.

Diagnosis 

• Urine studies include the following: 1. Urinalysis with microscopy 2. Urine culture to rule out infection, if suspected 3. Urinary tumor marker testing
• Urinary cytology 
• Cystoscopy
• Upper urinary tract imaging : CT Scan  PET CT Scan 
• Biomarker testing –  Newer molecular and genetic markers, including detection of mutations in genes such as RAS, FGFR3,PIK3CA, and TP53, may help in the early detection and prediction of urothelial carcinoma.
• Routine blood test – No blood tests are specific for bladder cancer, but a general evaluation is necessary prior to initiating therapy e.g. CBC, LFT, RFT, Bony fraction of alkaline phosphatase assay (if bone metastasis suspected.

Management and Traetment

• Surgery :  Complete TURBT (transurethral resection of bladder tumor) , Radical Cystectomy (removal of bladder and nearby organs)
• Intravesical Therapy: BCG (Bacillus Calmette-Guérin)
• Chemotherapy : Cisplatin-based regimen, Gemcitabine before cystectomy improves survival 
•  Immunotherapy : Used in PD-L1 positive patients or after chemo failure – Atezolizumab, Durvalumab, Nivolumab, Pembrolizumab.
• Targeted Therapies : Only if FGFR and  HER2 (genetic mutation) – positive patient
• Radiation Therapy : For the patients who want bladder Preservation – Used with chemotherapy 
• Palliative Care : Pain management, hematuria control, and symptom relief in advanced cases.

Follow-Up And Surveillance (After the completion of treatment)

• Bladder cancer has a high recurrence rate, so regular cystoscopy, urine tests, and imaging are essential
• Surveillance intervals depend on risk level and prior treatments.
• Usually Cystoscopy + urine cytology every 3–6 months (first 2 years), then less frequent
• Upper tract imaging yearly.
• Post Surgery –  Imaging (CT abdomen/pelvis) every 6–12 months  and monitor renal function, electrolytes, and metabolic parameters(especially in neobladder).

Your Role In Prevention

• Quit smoking and avoid secondhand smoke.
• Use protective gear if working with chemicals.
• Drink clean, filtered water.
• Don’t ignore urinary symptoms.
• Promote routine health screenings, especially in high-risk groups.

Let’s Raise Awareness Together

This Bladder Cancer Awareness Month, let’s unite to

• Educate ourselves and others.
• Encourage early consultations.
• Support ongoing cancer research and care.

At Shashwat Hospitals, we remain committed to early detection, comprehensive cancer care, and spreading awareness to save lives.

We provide:

• Screening and diagnosis for bladder cancer.
• Radiological and laboratory investigations, including biopsy.
• Advanced treatments like chemotherapy , immunotherapy, targeted therapy and surgical interventions.
• A well-known and experienced team of medical and surgical oncologists.
• Personalized treatment plans for all stages of bladder cancer.
• Guidance for cancer screening and risk assessment.
• E-clinic services for remote consultations and follow-up care.